eShowcase: EDC 2.0
New Version of EDC Solution Builds on Web Capabilities for Integration and Study Deployment
New Version of EDC Solution Builds on Web Capabilities for Integration and Study Deployment
etrials Worldwide (Morrisville, NC) has released EDC 2.0, the latest version of its software for pharmaceutical companies used to collect, manage, and analyze clinical trial information.
EDC 2.0 is Web-based and can integrate with etrials eDiary and IVR solutions to provide a more comprehensive e-clinical solution.
Also, because it is Web-based, it can be accessed by study sites and provides user-directed functions and design. The product also includes new reporting and configuration capabilities. Other functions include Electronic Case Report Forms (eCRF), workflow manager, a Message/Alert manager that uses a message center to connect and communicate with sites and investigators, a Reporting/Analytics function, and a Design Manager to improve application interfaces for increased user function.
Data is housed in a single data repository and includes the ability to integrate study-related data using Data Xchange.
etrials Worldwide, (919) 653-3400, www.etrials.com
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
